ausblenden:
Schlagwörter:
KINASE INHIBITOR; BETA-CATENIN; MEDIATOR COMPLEX; TRANSCRIPTION; CELLSPharmacology & Pharmacy; Sorafenib; CDK8; inhibitor; DMG-out;
Zusammenfassung:
Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.
